| Document Date: 2013-02-26 15:30:27
Open Document File Size: 339,13 KBShare Result on Facebook
City Reference / / Company Global Health Outcomes / ITT / Abbott Laboratories / / Facility Laboratory Abnormalities dn2400v17-redlined-niaspan-2013-jan-24 / Laboratory Abnormalities Increase / Laboratory Test Interactions / / MedicalCondition recurrent nonfatal myocardial infarction / glucose intolerance / atherosclerotic vascular disease / macular edema / Liver Dysfunction / Myopathy / nausea / anaphylaxis / Known hypersensitivity / syncope / gout / unstable angina / laryngismus / myopathy/rhabdomyolysis / tachycardia / Hypersensitivity / diarrhea / coronary heart disease / hepatitis / peptic ulcer disease / liver disease / pruritus / similar / fewer flushing episodes / active peptic ulcer disease / hypotension / mixed dyslipidemia / insomnia / peptic ulcer / necrosis / Flushing / Respiratory Cough / hepatobiliary disease / hypothyroidism / primary hyperlipidemia / dyspnea / shortness of breath / hypertriglyceridemia / chills / Carcinogenesis / hypophosphatemia / cardiac arrhythmias / atherosclerotic disease / stroke / dyslipidemia / unexplained hepatic dysfunction / Active liver disease / migraine / cardiovascular disease / diabetes / hyperlipidemia / itching / fever / acute coronary syndrome / rhabdomyolysis / Metabolic Syndrome / uncontrolled hypothyroidism / severe hypertriglyceridemia / vomiting / Gastrointestinal Disorders Diarrhea / myocardial infarction / diabetes mellitus / urticaria / angioedema / diseases / pancreatitis / postural hypotension / coronary artery disease / atrial fibrillation / dizziness / cough / renal failure / peptic ulcers / rash / paresthesia / / MedicalTreatment Concomitant therapy / surgery / statin therapy / adjunctive therapy / / Organization NIASPAN administration / DOSAGE AND ADMINISTRATION / FDA / / / Product simvastatin / niacin / Dosage 1 NIASPAN 500 / Impact / lovastatin / niaspan / / ProvinceOrState Michigan / / Technology Pharmacokinetics / Pharmacodynamics / CAD / / URL www.fda.gov/medwatch / /
SocialTag |
dn2400v17-redlined-niaspan-2013-jan-24 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use ® NIASPAN safely and effectively. See full prescribing information for NIASP